Photo of Jerome P. Richie,  MD

Jerome P. Richie, MD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-6227
Fax: (617) 525-6347


jrichie@partners.org

Jerome P. Richie, MD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Elliott Carr Cutler Professor of Surgery, Surgery, Harvard Medical School
  • Chief (Emeritus), Urology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

1. Signal transduction in prostate cancer

2. Telomerase

3. Predictors of response / failure in treatment of localized prostate cancer

Publications

Powered by Harvard Catalyst
  • Richie JP. Re: Testicular Cancer in Europe and the USA: Survival Still Rising among Older Patients. J Urol 2014; 191:1293. PubMed
  • Richie JP. Re: early development of the metabolic syndrome after chemotherapy for testicular cancer. J Urol 2014; 191:987. PubMed
  • Rose BS, Chen MH, Zhang D, Hirsch MS, Richie JP, Chang SL, Hegde JV, Loffredo MJ, D'Amico AV. Maximum Tumor Diameter and the Risk of Prostate-Specific Antigen Recurrence After Radical Prostatectomy. Clin Genitourin Cancer 2014. PubMed
  • Phillips JG, Aizer AA, Chen MH, Zhang D, Hirsch MS, Richie JP, Tempany CM, Williams S, Hegde JV, Loffredo MJ, D'Amico AV. The Effect of Differing Gleason Scores at Biopsy on the Odds of Upgrading and the Risk of Death From Prostate Cancer. Clin Genitourin Cancer 2014. PubMed
  • Richie JP. Re: tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. J Urol 2014; 191:659. PubMed
  • Richie JP. Re: dynamic contrast-enhanced subtraction MRI for characterizing intratesticular mass lesions. J Urol 2014; 191:363. PubMed
  • Tanguturi SK, Chen MH, Loffredo M, Richie JP, D'Amico AV. Evaluating the Impact of PSA as a Selection Criteria for Nerve Sparing Radical Prostatectomy in a Screened Cohort. Prostate Cancer 2014; 2014:395078. PubMed
  • Richie JP. Re: Pathological findings after primary chemotherapy in patients undergoing simultaneous orchidectomy and retroperitoneal lymph node dissection for advanced germ cell tumours. J Urol 2013; 190:2096. PubMed
  • Richie JP. Re: Anti-tumour activity of two novel compounds in cisplatin-resistant testicular germ cell cancer. J Urol 2013; 190:1767-8. PubMed
  • Richie JP. Re: An alternative treatment regimen of advanced seminoma with carboplatin, etoposide, and bleomycin instead of cisplatin-based therapy. J Urol 2013; 190:1251. PubMed
  • Richie JP. Re: A meta-analysis of the risk of boys with isolated cryptorchidism developing testicular cancer in later life. J Urol 2013; 190:1045. PubMed
  • Richie JP. Re: genomic characterization of testis cancer: association of alterations with outcome of clinical stage 1 mixed germ cell nonseminomatous germ cell tumor of the testis. J Urol 2013; 190:537-8. PubMed
  • Richie JP. Re: barriers to the implementation of surveillance for stage I testicular seminoma. J Urol 2013; 189:2110-1. PubMed
  • Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Penile cancer. J Natl Compr Canc Netw 2013; 11:594-615. PubMed
  • Richie JP. Re: real-time tissue elastography for testicular lesion assessment. J Urol 2013; 189:1719-20. PubMed
  • Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. Bladder cancer. J Natl Compr Canc Netw 2013; 11:446-75. PubMed
  • Richie JP. Re: clinical analysis of management of pediatric testicular germ cell tumors. J Urol 2013; 189:1532-3. PubMed
  • Richie JP. Re: second malignant neoplasms in testicular cancer survivors. J Urol 2013; 189:903. PubMed
  • Richie JP. Preclinical and clinical activity of sunitinib in patients with Cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group/German testicular cancer study group cooperative study. J Urol 2013; 189:533-4. PubMed
  • Richie JP. Re: Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. J Urol 2012; 189:128-9. PubMed
  • Richie JP. Re: incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. J Urol 2012; 188:2231-2. PubMed
  • Richie JP. Re: sequelae of treatment in long-term survivors of testis cancer. J Urol 2012; 188:1771. PubMed
  • Richie JP. Re: The clinical features and management of testicular germ cell tumours in patients aged 60 years and older. J Urol 2012; 188:1184-5. PubMed
  • Richie JP. Re: Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. J Urol 2012; 188:815-6. PubMed
  • Richie JP. Re: Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour. J Urol 2012; 188:434-5. PubMed
  • Richie JP. Re: First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Urol 2012; 188:115-6. PubMed
  • Williams SB, Hirsch MS, Kantoff PW, Richie JP. Neuroepithelial Tumor Arising in a Testicular Teratoma With Retroperitoneal Metastasis. J Clin Oncol 2012. PubMed
  • Liong ML, Lim CR, Yang H, Chao S, Bong CW, Leong WS, Das PK, Loh CS, Lau BE, Yu CG, Ooi EJ, Nam RK, Allen PD, Steele GS, Wassmann K, Richie JP, Liew CC. Blood-based biomarkers of aggressive prostate cancer. PLoS ONE 2012; 7:e45802. PubMed
  • Williams SB, Chen MH, D'Amico AV, Weinberg AC, Kacker R, Hirsch MS, Richie JP, Hu JC. Radical Retropubic Prostatectomy and Robotic-assisted Laparoscopic Prostatectomy: Likelihood of Positive Surgical Margin(s). Urology 2010; 76:1097-101. PubMed
  • Williams SB, McDermott DW, Winston D, Bahnson E, Berry AM, Steele GS, Richie JP. Morbidity of open retroperitoneal lymph node dissection for testicular cancer: contemporary perioperative data. BJU Int 2010; 105:918-21. PubMed
  • Williams SB, Kacker R, Steele GS, Richie JP. Primary vs. post-chemotherapy retroperitoneal lymph node dissection (RPLND) in patients with presence of teratoma at orchiectomy. Urol Oncol 2010. PubMed
  • Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, Richie JP, de la Rosette JJ. A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 2010; 57:223-32. PubMed
  • Williams SB, Steele GS, Richie JP. Primary retroperitoneal lymph node dissection in patients with clinical stage IS testis cancer. J Urol 2009; 182:2716-20. PubMed
  • Rayala HJ, Richie JP. Radical prostatectomy reigns supreme. Oncology (Huntingt) 2009; 23:863-7. PubMed
  • Williams SB,McDermott DW,Dock W,Bahnson E,Berry AM,Steele GS,Richie JP. Retroperitoneal lymph node dissection in patients with high risk testicular cancer. J Urol 2009; 181:2097-101; discussion 2101-2. PubMed
  • Prasad SM,Ferreria M,Berry AM,Lipsitz SR,Richie JP,Gawande AA,Hu JC. Surgical apgar outcome score: perioperative risk assessment for radical cystectomy. J Urol 2009; 181:1046-52; discussion 1052-3. PubMed
  • Barrisford GW,Sartor O,Richie JP. Solitary adrenal metastatic lesion in a patient with a history of prostate cancer. Clin Genitourin Cancer 2009; 7:64-6. PubMed
  • Montie JE,Clark PE,Eisenberger MA,El-Galley R,Greenberg RE,Herr HW,Hudes GR,Kuban DA,Kuzel TM,Lange PH,Lele SM,Michalski J,Patterson A,Pohar KS,Richie JP,Sexton WJ,Shipley WU,Small EJ,Trump DL,Walther PJ,Wilson TG. Bladder cancer. J Natl Compr Canc Netw 2009; 7:8-39. PubMed
  • Sommers BD,Beard CJ,D'Amico AV,Kaplan I,Richie JP,Zeckhauser RJ. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113:2058-67. PubMed
  • Silverman SG,Israel GM,Herts BR,Richie JP. Management of the incidental renal mass. Radiology 2008; 249:16-31. PubMed
  • Prasad SM,Keating NL,Wang Q,Pashos CL,Lipsitz S,Richie JP,Hu JC. Variations in surgeon volume and use of pelvic lymph node dissection with open and minimally invasive radical prostatectomy. Urology 2008; 72:647-52; discussion 652-3. PubMed
  • Richie JP. By the way, doctor. I have been taking Avodart for my BPH, along with Flomax, but finasteride may be less expensive. Should I switch? Harv Health Lett 2008; 33:8. PubMed
  • Richie JP. Is full bilateral retroperitoneal lymph node dissection always necessary for post-chemotherapy residual tumor? Beck SD, Foster RS, Bihrle R, Donohue JP, Einhorn LH, Department of Urology and Oncology, Indiana University Medical Center, Indianapolis, IN. Urol Oncol 2008; 26:218-9. PubMed
  • Richie JP. Impact of diagnostic delay in testis cancer: Results of a large population-based study Huyghe E, Muller A, Mieusset R, Bujan L, Bachaud JM, Chevreau C, Plante P, Thonneau P, Human Fertility Research Group, Paule de Viguier Hospital, Toulouse University II Urol Oncol 2008; 26:220-1. PubMed
  • Richie JP. Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors Carver BS, Serio AM, Bajorin D, Motzer RJ, Stasi J, Bosl GJ, Vickers AJ, Sheinfeld J. Department of Urology, Sidney Kimmel Center for Prostate and Urologic Urol Oncol 2008; 26:220. PubMed
  • Richie JP. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R, Division of Hematology-Oncology, Indiana University School of Medicine, Indianapolis, IN. Urol Oncol 2008; 26:218. PubMed
  • Richie JP. Prepubertal orchiopexy for cryptorchidism may be associated with lower risk of testicular cancer Walsh TJ, Dall'Era MA, Croughan MS, Carroll PR, Turek PJ, Department of Urology, University of California San Francisco, San Francisco, CA. Urol Oncol 2008; 26:219-20. PubMed
  • Alexis F, Rhee JW, Richie JP, Radovic-Moreno AF, Langer R, Farokhzad OC. New frontiers in nanotechnology for cancer treatment. Urol Oncol 2008; 26:74-85. PubMed
  • Sommers BD, Beard CJ, D'Amico AV, Dahl D, Kaplan I, Richie JP, Zeckhauser RJ. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer 2007; 110:2210-7. PubMed
  • Mukhopadhyay NK, Cinar B, Mukhopadhyay L, Lutchman M, Ferdinand AS, Kim J, Chung LW, Adam RM, Ray SK, Leiter AB, Richie JP, Liu BC, Freeman MR. The zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer. Mol Endocrinol 2007; 21:2056-70. PubMed
  • Richie J. By the way, doctor. I heard about a new test for prostate cancer that's better than the PSA test. Should I get this test? Harv Health Lett 2007; 32:8. PubMed
  • Richie JP Jr, Komninou D, Albino AP. Induction of colon tumorigenesis by glutathione depletion in p53-knock-out mice. Int J Oncol 2007; 30:1539-43. PubMed
  • Tsai HK, Chen MH, McLeod DG, Carroll PR, Richie JP, D'Amico AV. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer. Cancer 2006; 107:2597-603. PubMed
  • Mukhopadhyay NK, Ferdinand AS, Mukhopadhyay L, Cinar B, Lutchman M, Richie JP, Freeman MR, Liu BC. Unraveling androgen receptor interactomes by an array-based method: discovery of proto-oncoprotein c-Rel as a negative regulator of androgen receptor. Exp Cell Res 2006; 312:3782-95. PubMed
  • Rodrigues NA, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer. Cancer 2006; 107:514-20. PubMed
  • Hurwitz MD, Schultz D, Richie JP, Wein AJ, Whittington R, Malkowicz SB, D'Amico AV. Radical prostatectomy for high-grade prostate cancer. Urology 2006; 68:367-70. PubMed
  • Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright RL, Tormey L, Talcott J, Rubin MA, Loda M, Sellers WR, Richie JP, Kantoff PW, Weeks J. Development of an integrated prostate cancer research information system. Clin Genitourin Cancer 2006; 5:61-6. PubMed
  • Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 2006; 103:6315-20. PubMed
  • Galper SL, Chen MH, Catalona WJ, Roehl KA, Richie JP, D'Amico AV. Evidence to support a continued stage migration and decrease in prostate cancer specific mortality. J Urol 2006; 175:907-12. PubMed
  • Dvorak T, Chen MH, Renshaw AA, Loffredo M, Richie JP, D'Amico AV. Maximal tumor diameter and the risk of PSA failure in men with specimen-confined prostate cancer. Urology 2005; 66:1024-8. PubMed
  • McAleer SJ, Schultz D, Whittington R, Malkowicz SB, Renshaw A, Wein A, Richie JP, D'Amico AV. PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol 2005; 23:311-7. PubMed
  • Silverman SG, Tuncali K, vanSonnenberg E, Morrison PR, Shankar S, Ramaiya N, Richie JP. Renal tumors: MR imaging-guided percutaneous cryotherapy--initial experience in 23 patients. Radiology 2005; 236:716-24. PubMed
  • Febbo PG, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005; 11:5233-40. PubMed
  • Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology 2005; 65:528-32. PubMed
  • Bloom KD, Richie JP, Schultz D, Renshaw A, Saegaert T, D'amico AV. Invasion of seminal vesicles by adenocarcinoma of the prostate: PSA outcome determined by preoperative and postoperative factors. Urology 2004; 63:333-6. PubMed
  • D'amico AV, Tempany CM, Schultz D, Cormack RA, Hurwitz M, Beard C, Albert M, Kooy H, Jolesz F, Richie JP. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003; 62:1063-7. PubMed
  • Coen JJ, Zietman AL, Thakral H, Shipley WU. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 2002; 20:3199-205. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002; 95:281-6. PubMed
  • Lieberfarb ME, Schultz D, Whittington R, Malkowicz B, Tomaszewski JE, Weinstein M, Wein A, Richie JP, D'Amico AV. Using PSA, biopsy Gleason score, clinical stage, and the percentage of positive biopsies to identify optimal candidates for prostate-only radiation therapy. Int J Radiat Oncol Biol Phys 2002; 53:898-903. PubMed
  • Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002; 1:203-9. PubMed
  • Fielding JR, Hoyte LX, Okon SA, Schreyer A, Lee J, Zou KH, Warfield S, Richie JP, Loughlin KR, O'Leary MP, Doyle CJ, Kikinis R. Tumor detection by virtual cystoscopy with color mapping of bladder wall thickness. J Urol 2002; 167:559-62. PubMed
  • Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001; 276:13442-51. PubMed
  • Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV. Optimizing patient selection for prostate monotherapy. Int J Radiat Oncol Biol Phys 2001; 49:673-7. PubMed
  • Duque JL, Adam RM, Mullen JS, Lin J, Richie JP, Freeman MR. Heparin-binding epidermal growth factor-like growth factor is an autocrine mediator of human prostate stromal cell growth in vitro. J Urol 2000; 165:284-8. PubMed
  • D'Amico AV, Wu Y, Chen MH, Nash M, Renshaw AA, Richie JP. Pathologic findings and prostate specific antigen outcome after radical prostatectomy for patients diagnosed on the basis of a single microscopic focus of prostate carcinoma with a gleason score PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Silver B, Henry L, Hurwitz M, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol 2000; 4:171-5;discussion 177. PubMed
  • D'Amico AV, Weinstein M, Li X, Richie JP, Fujimoto J. Optical coherence tomography as a method for identifying benign and malignant microscopic structures in the prostate gland. Urology 2000; 55:783-7. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Fondurulia J, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 2000; 18:1164-72. PubMed
  • Catalona WJ, Partin AW, Slawin KM, Naughton CK, Brawer MK, Flanigan RC, Richie JP, Patel A, Walsh PC, Scardino PT, Lange PH, deKernion JB, Southwick PC, Loveland KG, Parson RE, Gasior GH. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. Urology 2000; 55:372-6. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Renshaw AA, Tomaszewski JE, Richie JP, Wein A. Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage. Int J Radiat Oncol Biol Phys 1999; 45:1227-33. PubMed
  • D'Amico AV, Desjardin A, Chen MH, Paik S, Schultz D, Renshaw AA, Loughlin KR, Richie JP. Analyzing outcome-based staging for clinically localized adenocarcinoma of the prostate. Cancer 1998; 83:2172-80. PubMed
  • Duque JL, Loughlin KR, O'Leary MP, Kumar S, Richie JP. Partial nephrectomy: alternative treatment for selected patients with renal cell carcinoma. Urology 1998; 52:584-90. PubMed
  • D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Loughlin KR, Richie JP, Wein A. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol 1998; 16:3094-100. PubMed
  • Renshaw AA, Richie JP, Loughlin KR, Jiroutek M, Chung A, D'Amico AV. The greatest dimension of prostate carcinoma is a simple, inexpensive predictor of prostate specific antigen failure in radical prostatectomy specimens. Cancer 1998; 83:748-52. PubMed
  • Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, Wishnow KI, Kaplan I, Loughlin KR, Richie JP, Kantoff PW. Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol 1998; 16:275-83. PubMed
  • Van den Abbeele AD, Tutrone RF, Berman RM, Baranowska-Kortylewicz J, Barclay PD, Richie JP, Adelstein SJ, Kassis AI. Tumor-targeting potential of radioiodinated iododeoxyuridine in bladder cancer. J Nucl Med 1996; 37:315-20. PubMed
Hide